RARE DISEASE
Photosensitive epilepsy
Photosensitive epilepsy
Photosensitive epilepsy
Drug discovery
0
drugs
With orphan designations
Overview
Photosensitive epilepsy is a reflex epilepsy syndrome where seizures are triggered by visual stimuli like flashing lights (3-60 Hz) or high-contrast patterns. It accounts for 3-5% of epilepsy cases, predominantly affecting females and adolescents aged 7-19 years [1][6][10]. Diagnosis involves EEG with photoparoxysmal responses during intermittent photic stimulation [1][10]. First-line treatment combines anti-seizure medications (ASMs) with trigger avoidance strategies [3][11][14].
Therapies
Pharmacologic: Valproate (73-86% efficacy), levetiracetam, lamotrigine; avoid sodium channel blockers like carbamazepine [3][7][11]
Non-pharmacologic: Stimulus control (≥2m screen distance, blue-tinted glasses), one-eye covering during exposures [7][15][19]
Lifestyle: Sleep optimization, alcohol avoidance, and VR/content warnings [1][14][19]
Categories: rare neurological diseases
Research Papers
522 drug discovery papers about Photosensitive epilepsy. Recent publications:
522 drug discovery papers about Photosensitive epilepsy. Recent publications:
2026-03-15 | From clinical practice to mechanistic insights in ketogenic diets for epilepsy.
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have shown effectiveness in controlling seizures, in part by shifting metabolism from glucose to ketone bodies. They improve mitochondrial function, reduce neuroinflammation, and modulate neurotransmitters. Ketogenic diet therapies also affect the gut microbiome, potentially impacting neurotransmitter balance in ways that contribute to seizure control. A classic ketogenic diet is effective yet restrictive, whereas the modified Atkins diet and low glycaemic index treatment offer greater flexibility, tolerability, and ease of implementation, particularly in resource-limited settings. Cochrane reviews and meta-analyses rank the certainty of randomised controlled trial evidence for ketogenic diet therapies as limited. Early initiation of ketogenic diet therapies, particularly in children or patients with metabolic epilepsies, improves seizure outcomes, potentially preventing further mitochondrial and neuronal damage and reducing the risk of developing resistance to antiseizure medications. Research using rigorous, large-scale comparative effectiveness study designs that accounts for differences in age, epilepsy type, dietary therapy modality, sociodemographic background, care delivery contexts, and that minimises performance and observation bias is needed to resolve remaining uncertainties regarding the efficacy and real-world challenges of ketogenic diet therapies in epilepsy.
2026-03-03 | Lenses protecting against photosensitivity violate international driving regulations
To the Editors: The insightful review on visually provoked seizures by Fisher et al.1 provides relevant and valuable information on a broad range of aspects related to photosensitivity and epilepsy. This includes potential real-life trigger situations, such as a risk that may be posed by flickering light at frequencies associated with a high susceptibility to photoparoxysmal responses when driving along an avenue at dawn or sunset. As a nonpharmacological treatment option to protect patients with photoparoxysmal responses, dark lenses and blue lenses—particularly the Zeiss Z1 blue lens—are discussed due to their ability to reduce or even abolish photosensitivity, as demonstrated in several studies (e.g., Takahashi and Tsukahara,2 Capovilla et al.3). In particular, the review notes that, when driving a car, tinted glasses with reduced light transmission are recommended. At the same time, however, the authors emphasize that lenses impairing the perception of orange traffic signals should be avoided. We would like to highlight this latter point, as it is highly relevant when considering the use of tinted lenses in photosensitive patients who drive. Dark sunglasses are unsuitable for driving at sunset or during nighttime due to their reduced light transmission.4 In addition, the Z1 lens—and blue lenses in general—substantially alter the spectral composition of transmitted light by selectively attenuating longer wavelengths of the visible spectrum. This results in a marked reduction in the visibility of red and orange visual stimuli. Such stimuli are critical in traffic, particularly for the recognition of traffic lights as well as the brake lights and taillights of vehicles (Figure 1). Attenuation of red light intensity may delay stimulus recognition and consequently prolong reaction times while driving. Therefore, although these lenses may exert beneficial effects in reducing photosensitivity, they may simultaneously increase the risk of traffic accidents. Accordingly, blue lenses—and especially Z1 lenses, which have the strongest evidence for suppressing photosensitivity—are not considered suitable for driving according to the International Organization for Standardization (ISO 12312-1:2022). Prescribing colored or dark lenses for patients with purely visually provoked seizures who may be legally permitted to drive once the triggering stimulus is suppressed therefore requires careful consideration of both their beneficial effects and potentially associated risks, as well as implications with regard to driving regulations. Open Access funding enabled and organized by Projekt DEAL. None of the authors has any conflict of interest related to this letter to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. ISO 12312-1:2022, p. 6 (Requirements for road use and driving): Filters suitable for road use and driving shall additionally meet the following two requirements: Spectral transmittance. The spectral transmittance of filters suitable for road use and driving for wavelengths between 475 and 650 nm shall be not less than 0.20 τv D65. Detection of signal lights. The relative visual attenuation quotient Q of filters of categories 0, 1, 2 and 3 suitable for road use and driving shall be not less than 0.80 for red signal light and not less than 0.60 for yellow, green and blue signal lights.
2026-03-03 | Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.
Seletracetam (SEL) is a second-generation racetam derivative of the benchmark antiseizure medication (ASM) levetiracetam, discovered in a drug discovery program conducted by UCB Pharma in the early 2000s to optimize binding to synaptic vesicle glycoprotein 2A (SV2A), the main target of levetiracetam. SEL (administered orally) reached phase IIa clinical trials, but its further development was stopped, and its patent expired in 2021. In preclinical studies, SEL showed very potent seizure suppression in several acquired and genetic epilepsy models, with high CNS tolerability. Phase I human studies indicated rapid and extensive oral absorption (> 90% bioavailability), linear pharmacokinetics, and an elimination half-life of about 8 h, with mostly mild to moderate CNS adverse events. Several phase IIa trials found SEL to be effective and to have a good safety profile in patients with photosensitive epilepsy and drug-resistant focal epilepsy. A unique aspect of SEL is its high potency and water solubility that-unlike any other non-benzodiazepine (non-BDZ) ASMs-allows it to be formulated at therapeutic doses in a very low liquid volume suitable for intranasal administration and potential use in acute seizure rescue therapy. The US-based company PrevEp, Inc. (Bethesda, MD) filed a new US patent application in 2024, followed by a worldwide Patent Cooperation Treaty (PCT) application in 2025 on intranasal and orobuccal SEL formulations and new medical uses as the first potential non-BDZ rescue treatment of acute repetitive seizures and rapid epileptic seizure termination (REST). The clinical development of this novel formulation is derisked by the favorable oral SEL administration phase I and phase IIa clinical data. SEL offers several important advantages for rescue treatment in comparison with BZDs. It is only moderately sedative even at the highest doses tested orally, does not cause respiratory depression, and has no addictive potential. Thus, SEL has the potential to become the first non-BDZ acute rescue therapy. Because SEL has never been approved for use in humans, it is a new chemical entity (NCE). In this review, we describe the pharmacology of SEL, its clinical profile after oral administration, and the development of the new intranasal formulation, including first-in-human data.
2026-02-13 | RASP-Seizure: A Recursive Attractor Model of Photosensitive Epilepsy with Application to Sunflower Syndrome
Applies the Recursive Attractor Stability Principle (RASP) to model seizure dynamics in photosensitive epilepsy, with specific application to Sunflower Syndrome. The identical recursion f(x) = 25·tanh³(x) − x/124 that derives the proton mass predicts: seizure modes are quantized, the three-node circuit (V1 + Thalamus + Motor) is uniquely seizure-prone via Diophantine selection, peak photosensitivity at 18 Hz (clinical range 15-20 Hz), dual-mechanism drugs outperform single-mechanism (validated: fenfluramine 89% vs levetiracetam 0%), and anti-resonant frequencies exist for non-pharmacological intervention. Validated against 56 primary sources. The sole genetic variant found in Sunflower Syndrome (GABRG2 p.Trp429Ter) destroys a tryptophan — the RASP-critical amino acid. The ratio p/n = 5/3 is the major sixth in just intonation, connecting seizure compulsion to musical anticipation through shared dopaminergic pathways. Ten testable predictions with explicit kill criteria. Fourth paper in the CUFT-RASP series. Research began June 2025. v0.6.
2026-02-12 | The Pokémon Shock of 1997: A Comprehensive Analysis of Television-Induced Photosensitive Seizures and Mass Psychogenic Illness
On December 16, 1997, an unprecedented public health incident occurred in Japan when an episode of the animated television series Pokémon triggered adverse neurological reactions in thousands of viewers. This event, known as the “Pokémon Shock” or “Pokémon Incident,” resulted in more than 600 hospitalizations and affected an estimated 12,000 children nationwide. This paper presents a comprehensive analysis of the incident, examining the mechanisms of photosensitive epilepsy, the role of mass psychogenic illness, the immediate medical and regulatory responses, and the long-term impact on broadcast standards. Through a systematic review of medical literature, regulatory documents, and epidemiological data, we demonstrate that the incident resulted from a complex interplay between genuine photosensitive epilepsy in susceptible individuals and mass sociogenic illness amplified by extensive media coverage. The event led to the establishment of strict broadcasting guidelines that later became international standards, fundamentally transforming animation production practices worldwide. This case study offers valuable insights into the intersection of media technology, neurology, public health policy, and mass psychology.
2026-03-15 | From clinical practice to mechanistic insights in ketogenic diets for epilepsy.
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have shown effectiveness in controlling seizures, in part by shifting metabolism from glucose to ketone bodies. They improve mitochondrial function, reduce neuroinflammation, and modulate neurotransmitters. Ketogenic diet therapies also affect the gut microbiome, potentially impacting neurotransmitter balance in ways that contribute to seizure control. A classic ketogenic diet is effective yet restrictive, whereas the modified Atkins diet and low glycaemic index treatment offer greater flexibility, tolerability, and ease of implementation, particularly in resource-limited settings. Cochrane reviews and meta-analyses rank the certainty of randomised controlled trial evidence for ketogenic diet therapies as limited. Early initiation of ketogenic diet therapies, particularly in children or patients with metabolic epilepsies, improves seizure outcomes, potentially preventing further mitochondrial and neuronal damage and reducing the risk of developing resistance to antiseizure medications. Research using rigorous, large-scale comparative effectiveness study designs that accounts for differences in age, epilepsy type, dietary therapy modality, sociodemographic background, care delivery contexts, and that minimises performance and observation bias is needed to resolve remaining uncertainties regarding the efficacy and real-world challenges of ketogenic diet therapies in epilepsy.
2026-03-03 | Lenses protecting against photosensitivity violate international driving regulations
To the Editors: The insightful review on visually provoked seizures by Fisher et al.1 provides relevant and valuable information on a broad range of aspects related to photosensitivity and epilepsy. This includes potential real-life trigger situations, such as a risk that may be posed by flickering light at frequencies associated with a high susceptibility to photoparoxysmal responses when driving along an avenue at dawn or sunset. As a nonpharmacological treatment option to protect patients with photoparoxysmal responses, dark lenses and blue lenses—particularly the Zeiss Z1 blue lens—are discussed due to their ability to reduce or even abolish photosensitivity, as demonstrated in several studies (e.g., Takahashi and Tsukahara,2 Capovilla et al.3). In particular, the review notes that, when driving a car, tinted glasses with reduced light transmission are recommended. At the same time, however, the authors emphasize that lenses impairing the perception of orange traffic signals should be avoided. We would like to highlight this latter point, as it is highly relevant when considering the use of tinted lenses in photosensitive patients who drive. Dark sunglasses are unsuitable for driving at sunset or during nighttime due to their reduced light transmission.4 In addition, the Z1 lens—and blue lenses in general—substantially alter the spectral composition of transmitted light by selectively attenuating longer wavelengths of the visible spectrum. This results in a marked reduction in the visibility of red and orange visual stimuli. Such stimuli are critical in traffic, particularly for the recognition of traffic lights as well as the brake lights and taillights of vehicles (Figure 1). Attenuation of red light intensity may delay stimulus recognition and consequently prolong reaction times while driving. Therefore, although these lenses may exert beneficial effects in reducing photosensitivity, they may simultaneously increase the risk of traffic accidents. Accordingly, blue lenses—and especially Z1 lenses, which have the strongest evidence for suppressing photosensitivity—are not considered suitable for driving according to the International Organization for Standardization (ISO 12312-1:2022). Prescribing colored or dark lenses for patients with purely visually provoked seizures who may be legally permitted to drive once the triggering stimulus is suppressed therefore requires careful consideration of both their beneficial effects and potentially associated risks, as well as implications with regard to driving regulations. Open Access funding enabled and organized by Projekt DEAL. None of the authors has any conflict of interest related to this letter to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. ISO 12312-1:2022, p. 6 (Requirements for road use and driving): Filters suitable for road use and driving shall additionally meet the following two requirements: Spectral transmittance. The spectral transmittance of filters suitable for road use and driving for wavelengths between 475 and 650 nm shall be not less than 0.20 τv D65. Detection of signal lights. The relative visual attenuation quotient Q of filters of categories 0, 1, 2 and 3 suitable for road use and driving shall be not less than 0.80 for red signal light and not less than 0.60 for yellow, green and blue signal lights.
2026-03-03 | Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.
Seletracetam (SEL) is a second-generation racetam derivative of the benchmark antiseizure medication (ASM) levetiracetam, discovered in a drug discovery program conducted by UCB Pharma in the early 2000s to optimize binding to synaptic vesicle glycoprotein 2A (SV2A), the main target of levetiracetam. SEL (administered orally) reached phase IIa clinical trials, but its further development was stopped, and its patent expired in 2021. In preclinical studies, SEL showed very potent seizure suppression in several acquired and genetic epilepsy models, with high CNS tolerability. Phase I human studies indicated rapid and extensive oral absorption (> 90% bioavailability), linear pharmacokinetics, and an elimination half-life of about 8 h, with mostly mild to moderate CNS adverse events. Several phase IIa trials found SEL to be effective and to have a good safety profile in patients with photosensitive epilepsy and drug-resistant focal epilepsy. A unique aspect of SEL is its high potency and water solubility that-unlike any other non-benzodiazepine (non-BDZ) ASMs-allows it to be formulated at therapeutic doses in a very low liquid volume suitable for intranasal administration and potential use in acute seizure rescue therapy. The US-based company PrevEp, Inc. (Bethesda, MD) filed a new US patent application in 2024, followed by a worldwide Patent Cooperation Treaty (PCT) application in 2025 on intranasal and orobuccal SEL formulations and new medical uses as the first potential non-BDZ rescue treatment of acute repetitive seizures and rapid epileptic seizure termination (REST). The clinical development of this novel formulation is derisked by the favorable oral SEL administration phase I and phase IIa clinical data. SEL offers several important advantages for rescue treatment in comparison with BZDs. It is only moderately sedative even at the highest doses tested orally, does not cause respiratory depression, and has no addictive potential. Thus, SEL has the potential to become the first non-BDZ acute rescue therapy. Because SEL has never been approved for use in humans, it is a new chemical entity (NCE). In this review, we describe the pharmacology of SEL, its clinical profile after oral administration, and the development of the new intranasal formulation, including first-in-human data.
2026-02-13 | RASP-Seizure: A Recursive Attractor Model of Photosensitive Epilepsy with Application to Sunflower Syndrome
Applies the Recursive Attractor Stability Principle (RASP) to model seizure dynamics in photosensitive epilepsy, with specific application to Sunflower Syndrome. The identical recursion f(x) = 25·tanh³(x) − x/124 that derives the proton mass predicts: seizure modes are quantized, the three-node circuit (V1 + Thalamus + Motor) is uniquely seizure-prone via Diophantine selection, peak photosensitivity at 18 Hz (clinical range 15-20 Hz), dual-mechanism drugs outperform single-mechanism (validated: fenfluramine 89% vs levetiracetam 0%), and anti-resonant frequencies exist for non-pharmacological intervention. Validated against 56 primary sources. The sole genetic variant found in Sunflower Syndrome (GABRG2 p.Trp429Ter) destroys a tryptophan — the RASP-critical amino acid. The ratio p/n = 5/3 is the major sixth in just intonation, connecting seizure compulsion to musical anticipation through shared dopaminergic pathways. Ten testable predictions with explicit kill criteria. Fourth paper in the CUFT-RASP series. Research began June 2025. v0.6.
2026-02-12 | The Pokémon Shock of 1997: A Comprehensive Analysis of Television-Induced Photosensitive Seizures and Mass Psychogenic Illness
On December 16, 1997, an unprecedented public health incident occurred in Japan when an episode of the animated television series Pokémon triggered adverse neurological reactions in thousands of viewers. This event, known as the “Pokémon Shock” or “Pokémon Incident,” resulted in more than 600 hospitalizations and affected an estimated 12,000 children nationwide. This paper presents a comprehensive analysis of the incident, examining the mechanisms of photosensitive epilepsy, the role of mass psychogenic illness, the immediate medical and regulatory responses, and the long-term impact on broadcast standards. Through a systematic review of medical literature, regulatory documents, and epidemiological data, we demonstrate that the incident resulted from a complex interplay between genuine photosensitive epilepsy in susceptible individuals and mass sociogenic illness amplified by extensive media coverage. The event led to the establishment of strict broadcasting guidelines that later became international standards, fundamentally transforming animation production practices worldwide. This case study offers valuable insights into the intersection of media technology, neurology, public health policy, and mass psychology.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.